Cargando…

Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer

PURPOSE: To investigate the contribution of PALB2 pathogenic gene variants (PGVs, PALB2_PGV) and the CHEK2 c.1100delC (CHEK2_1100delC) PGV to familial breast and ovarian cancer, and PALB2_PGV associated breast cancer pathology. METHODS: Outcomes of germline PALB2_PGV and CHEK2_1100delC testing were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Woodward, Emma R., van Veen, Elke M., Forde, Claire, Harkness, Elaine F., Byers, Helen J., Ellingford, Jamie M., Burghel, George J., Schlech, Helene, Bowers, Naomi L., Wallace, Andrew J., Howell, Sacha J., Howell, Anthony, Lalloo, Fiona, Newman, William G., Smith, Miriam J., Gareth Evans, D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486655/ https://www.ncbi.nlm.nih.gov/pubmed/34113003 http://dx.doi.org/10.1038/s41436-021-01234-6

Ejemplares similares

CHEK2 (∗)1100delC Mutation and Risk of Prostate Cancer
por: Hale, Victoria, et al.
Publicado: (2014)

CHEK2 1100delC in patients with metachronous cancers of the breast and the colorectum
por: Isinger, Anna, et al.
Publicado: (2006)

CHEK2 1100 delC mutation in Russian ovarian cancer patients
por: Krylova, Nadezhda Yu, et al.
Publicado: (2007)

Genomic profiling of CHEK2*1100delC-mutated breast carcinomas
por: Massink, Maarten P. G., et al.
Publicado: (2015)

Genetic modifiers of CHEK2*1100delC associated breast cancer risk
por: Muranen, Taru A., et al.
Publicado: (2016)

The CHEK2(*)1100delC mutation has no major contribution in oesophageal carcinogenesis
por: Koppert, L B, et al.
Publicado: (2004)

Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers
por: Kriege, Mieke, et al.
Publicado: (2015)

CHEK2 1100delC is prevalent in Swedish early onset familial breast cancer
por: Margolin, Sara, et al.
Publicado: (2007)

Frequency of CHEK2*1100delC in New York breast cancer cases and controls
por: Offit, Kenneth, et al.
Publicado: (2003)

A Case of Male Breast Cancer Patient with CHEK2*1100delC Mutation
por: Nguyen, Quan D, et al.
Publicado: (2020)

Risk for contralateral breast cancer among carriers of the CHEK2(*)1100delC mutation in the WECARE Study
por: Mellemkjær, L, et al.
Publicado: (2008)

Mutation screening of BRCA1, BRCA2 and CHEK2*1100delC in Slovak HBOC families
por: Cierniková, S, et al.
Publicado: (2005)

A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients
por: Wendt, Camilla, et al.
Publicado: (2021)

BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer
por: Francies, F. Z., et al.
Publicado: (2015)

Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy
por: Kriege, M, et al.
Publicado: (2014)

Breast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications
por: Muranen, Taru A, et al.
Publicado: (2011)

Frequency of the CHEK2 1100delC mutation among women with early-onset and bilateral breast cancer
por: Ding, Dapeng, et al.
Publicado: (2012)

CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population
por: Hallamies, Sanna, et al.
Publicado: (2017)

Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer‐specific survival
por: Morra, Anna, et al.
Publicado: (2023)

The CHEK2 1100delC allelic variant is not present in familial and sporadic breast cancer cases from Moroccan population
por: Marouf, Chaymaa, et al.
Publicado: (2015)

Low frequency of CHEK2 1100delC allele in Australian multiple-case breast cancer families: functional analysis in heterozygous individuals
por: Jekimovs, C R, et al.
Publicado: (2005)

Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival
por: Morra, Anna, et al.
Publicado: (2023)

Extended gene panel testing in lobular breast cancer
por: van Veen, Elke M., et al.
Publicado: (2021)

Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma
por: Thibodeau, My Linh, et al.
Publicado: (2017)

Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile
por: Smid, Marcel, et al.
Publicado: (2023)

Gene Panel Testing for Breast Cancer Reveals Differential Effect of Prior BRCA1/2 Probability
por: Evans, D. Gareth, et al.
Publicado: (2021)

Corrigendum: Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma
por: Thibodeau, My Linh, et al.
Publicado: (2018)

High likelihood of actionable pathogenic variant detection in breast cancer genes in women with very early onset breast cancer
por: Evans, D Gareth, et al.
Publicado: (2022)

Familial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk
por: Varley, Jenny, et al.
Publicado: (2003)

CHEK2 C1100del mutation associated with papillary renal cell carcinoma type II
por: Lopez, Santiago J., et al.
Publicado: (2023)

The checkpointkinase 2 (CHK2) 1100delC germ line mutation is not associated with the development of squamous cell carcinoma of the head and neck (SCCHN)
por: Scheckenbach, Kathrin, et al.
Publicado: (2010)

The importance of ethnicity: Are breast cancer polygenic risk scores ready for women who are not of White European origin?
por: Evans, D. Gareth, et al.
Publicado: (2021)

Risk of Contralateral Breast Cancer in Women with and without Pathogenic Variants in BRCA1, BRCA2, and TP53 Genes in Women with Very Early-Onset (<36 Years) Breast Cancer
por: Hyder, Zerin, et al.
Publicado: (2020)

PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS
por: Southey, Melissa C, et al.
Publicado: (2016)

Incorporating Truncating Variants in PALB2, CHEK2 and ATM into the BOADICEA Breast Cancer Risk Model
por: Lee, Andrew J., et al.
Publicado: (2016)

Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women
por: Evans, D. Gareth, et al.
Publicado: (2021)

Recontacting non-BRCA1/2 breast cancer patients for germline CHEK2 c.1100del pathogenic variant testing: uptake and patient experiences
por: Velthuizen, Mary E., et al.
Publicado: (2021)

Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer
por: Łukomska, Alicja, et al.
Publicado: (2021)

Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor
por: Ogrodniczak, Alicja, et al.
Publicado: (2022)

Uptake of bilateral-risk-reducing-mastectomy: Prospective analysis of 7195 women at high-risk of breast cancer
por: Evans, D.Gareth, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_globdvi0t1370ebdp23nnubjac